Stock Analysis
Prolight Diagnostics (NGM:PRLD) First Quarter 2024 Results
Key Financial Results
- Revenue: kr3.40m (down 2.7% from 1Q 2023).
- Net loss: kr8.93m (loss widened by 18% from 1Q 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Prolight Diagnostics shares are down 15% from a week ago.
Risk Analysis
You should always think about risks. Case in point, we've spotted 6 warning signs for Prolight Diagnostics you should be aware of, and 5 of them are a bit unpleasant.
Valuation is complex, but we're helping make it simple.
Find out whether Prolight Diagnostics is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.
View the Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About NGM:PRLD
Prolight Diagnostics
Develops diagnostic systems used in point of care testing in Sweden.
Adequate balance sheet and slightly overvalued.
